Bayer Stock Sidelined: Settlement Opt-Out Deadline Passes Without Spin-Off Catalyst

Bayer shares slip below key moving average after ruling out Monsanto spin-off, with legal risks from glyphosate settlement and Supreme Court case dictating next move.

Bayer’s shares ended Thursday at €35.39, a hair below the 200-day moving average of €35.76 — a level chartists treat as the dividing line between stability and fresh weakness. That technical warning arrived on the same day the company confirmed it has no immediate plans to hive off Monsanto, dashing hopes that a structural shake-up could unlock value. The convergence of these two developments leaves the stock in a precarious holding pattern, with the next big move depending almost entirely on how the US glyphosate litigation plays out.

The opt-out deadline in Bayer’s proposed $7.25 billion settlement covering more than 60,000 claimants expired on Thursday. Success hinges on near-universal participation — the company needs close to 100% of plaintiffs to remain in the deal. Separately, the “Durnell” case pending before the US Supreme Court will test a fundamental legal question: can a company be held liable under state law when the EPA has deemed the product safe? A decision is expected before the current term ends in June. Either outcome could either relieve or amplify pressure on the stock.

On the corporate structure front, Bayer poured cold water on speculation about a Monsanto spin-off. Reuters quoted a company representative saying the focus remains on operational improvements and managing legal disputes. Many investors had bet that a clean break from the herbicides business would help the market re-rate the stock. Without that catalyst, the equity story now depends on a slower, more grinding turnaround — a path the market rarely rewards generously while legal clouds persist. The shares have slipped 2.99% over the past week and sit 6.93% below their year-end close.

Operationally, Bayer is not standing still. Crop Science posted a stronger first-quarter result, and the Pharmaceuticals division is gaining traction with Nubeqa and Kerendia, though patent cliffs remain a drag. Pipeline updates — including new steps for Kerendia, Finerenon, the FXIa inhibitor, and Sevabertinib — underpin the long-term narrative. Yet these advances cannot immediately resolve the valuation questions tied to legal uncertainty or the lack of a clear structural path. The company reiterated its currency-adjusted full-year guidance after the first quarter, but the market is looking for more tangible progress on risk reduction.

Technically, the picture has turned patchy. The stock now trades below all three key moving averages: the 50-day at €38.43, the 100-day at €40.58, and the 200-day at €35.76. The 14-day relative strength index sits at 39.0, flirting with oversold territory but not yet flashing a clear reversal signal. Annualized 30-day volatility of 38% underlines how jittery investors remain. On the upside, recapturing the 200-day line would provide some breathing room; on the downside, the €33–€34 zone is the next major support floor.

Despite the recent slide, Bayer shares have still rallied 34.64% over the past twelve months. That recovery from the €25.09 twelve-month low shows that some confidence has returned. But the current price is 29.12% below the 52-week high of €49.93 — a gap that highlights the lingering brittleness. Until the legal calendar offers a decisive breakthrough — either through a high participation rate in the settlement or a favorable Supreme Court ruling — the stock seems condemned to oscillate between turnaround hope and liability fear. The spin-off option, for now, remains firmly on the shelf.